Answers are grounded in this paper and cite their sources.
The development of cell therapy as a widely available clinical option for ischaemic cardiomyopathy is hindered by the invasive nature of current cell delivery methods. Furthermore, the rapid disappearance of cells after transplantation provides a cogent rationale for using repeated cell doses, which, however, has not been done thus far in clinical trials because it is not feasible with invasive approaches. The goal of this translational study was to test the therapeutic utility of the intravenous route for cell delivery.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: